Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.
Alexandre ValléeYves LecarpentierJean-Noël ValléePublished in: Molecular psychiatry (2021)
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD.
Keyphrases
- obsessive compulsive disorder
- oxidative stress
- cell proliferation
- deep brain stimulation
- clinical trial
- stem cells
- end stage renal disease
- dna damage
- ischemia reperfusion injury
- diabetic rats
- induced apoptosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- signaling pathway
- prognostic factors
- randomized controlled trial
- pi k akt
- epithelial mesenchymal transition
- emergency department
- risk assessment
- bone marrow
- human health
- adverse drug
- electronic health record